News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Igenica, Inc. Awarded SBIR Grant For Next Generation Antibody Drug Conjugate Technology



8/7/2014 10:30:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURLINGAME, Calif.--(BUSINESS WIRE)--Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), announced today the award of a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology. SNAP technology, named for its speed and ease of use, overcomes the major limitations of current approaches by providing a simple, chemically-driven method for linking any anti-cancer antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios of drug to antibody.

Help employers find you! Check out all the jobs and post your resume

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES